Lupin rose 1.25% to Rs 900 at 13:58 IST on BSE after consolidated net profit surged 40% to Rs 406.20 crore on 18% growth in net sales to Rs 2631.50 crore in Q2 September 2013 over Q2 September 2012.
The Q2 result was announced during trading hours today, 30 October 2013.
Meanwhile, the S&P BSE Sensex was up 130.87 points or 0.63% at 21,059.88.
On BSE, 1.76 lakh shares were traded in the counter as against average daily volume of 1.24 lakh shares in the past one quarter.
The stock hit a high of Rs 910 and a low of Rs 895 so far during the day. The stock had hit a record high of Rs 946.35 on 11 October 2013. The stock had hit a 52-week low of Rs 557.10 on 19 November 2012.
The stock had underperformed the market over the past one month till 29 October 2013, advancing 4.16% compared with the Sensex's 6.09% rise. The scrip had also underperformed the market in past one quarter, gaining 3.78% as against Sensex's 6.82% rise.
The large-cap company has equity capital of Rs 89.61 crore. Face value per share is Rs 2.
Lupin's consolidated EBITDA (earnings before interest, taxation, depreciation and amortization) surged 42% to Rs 741 crore in Q2 September 2013 over Q2 September 2012.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and active pharmaceutical ingredients.
Powered by Capital Market - Live News
